Scilex Holding (SCLX) Intangibles (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Intangibles of $59.8 million for Q1 2026, up 90.16% year-over-year from $31.5 million in Q1 2025, and up 1.22% quarter-over-quarter from $59.1 million in Q4 2025.
Scilex Holding (SCLX) Intangibles (2021 - 2026) Analysis & Trends
Scilex Holding's Intangibles history runs 6 years deep, the most recent figure standing at $59.8 million for Q1 2026.
- In Q1 2026, Intangibles rose 90.16% year-over-year to $59.8 million; the TTM figure through Mar 2026 stood at $59.8 million (up 90.16% YoY), while the FY2025 annual figure was $59.1 million, up 82.07% from the prior year.
- Intangibles for Q1 2026 stood at $59.8 million, up from $59.1 million in the prior quarter.
- The five-year high for Intangibles was $61.8 million in Q2 2025, with the low at $5.0 million in Q1 2022.
- The 5-year median for Intangibles is $60.8 million (2022), against an average of $46.0 million.
- The sharpest annual moves came in 2023 and 2024: Intangibles jumped 1115.62% in 2023, then sank 46.61% in 2024.
- Scilex Holding's Intangibles stood at $60.8 million in 2022, then changed by 0.0% to $60.8 million in 2023, then tumbled by 46.61% to $32.5 million in 2024, then surged by 82.07% to $59.1 million in 2025, then rose by 1.22% to $59.8 million in 2026.
- Business Quant data shows SCLX's Intangibles at $59.8 million in Q1 2026, $59.1 million in Q4 2025, and $61.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Scilex Holding | 39.97 Mn | -72.82 Mn | 3.97 Mn | 94.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.81 Mn |
| Dec 31, 2025 | 59.09 Mn |
| Sep 30, 2025 | 61.78 Mn |
| Jun 30, 2025 | 61.78 Mn |
| Mar 31, 2025 | 31.45 Mn |
| Dec 31, 2024 | 32.45 Mn |
| Sep 30, 2024 | 60.78 Mn |
| Jun 30, 2024 | 60.78 Mn |
| Mar 31, 2024 | 35.46 Mn |
| Dec 31, 2023 | 60.78 Mn |
| Sep 30, 2023 | 60.78 Mn |
| Jun 30, 2023 | 60.78 Mn |
| Mar 31, 2023 | 60.78 Mn |
| Dec 31, 2022 | 60.78 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 38.80 Mn |